Abstract 422P
Background
The key roles of the TP53 mutation in cancer have been well established. However, the molecular mechanism differences of prostate cancer (PC) stratified by the TP53 mutation status has not yet been described.
Methods
Patients diagnosed with prostate cancer were enrolled in the study. Tumor tissue and matching blood were sequenced by next-generation sequencing (NGS) techniques with AcornMed panel with 808 cancer-related genes. Comprehensive molecular characterization was analyzed.
Results
A total of 599 patients with PC were enrolled including 90 patients with TP53 mutation (mut) and 509 patients with TP53 wild-type (wt). In TP53 mutation cohorts, the five most frequently mutated genes were TP53 (100%), BRD4 (19%), KMT2D (18%), ATRX (17%), and BRCA2 (15%). For TP53 wt cohorts, the five most frequently mutated genes were BRD4 (18%), AR (14%), FOXA1 (13%), CDK12 (12%), and BBC3 (11%). 88 frequently mutated genes were significant difference between TP53-mut and TP53-wt cohorts, such as KMT2D, ATRX, KMT2C, BRCA2 and PTEN, excluding the TP53 gene. There was no distinct signature between TP53-mut and TP53-wt cohorts. Signature 13 for APOBEC Cytidine Deaminase signatures, signature 5 for aging and signature 6 for defective DNA mismatch repair were only existed in TP53-mut cohorts, whereas signature 1 for spontaneous deamination of 5−methylcytosine and signature 3 for defects in DNA−DSB repair by HR were only discovered in TP53 wildtype cohorts. In the TP53 mutation cohorts, mutated genes were mainly enriched in the cancer pathway, PI3K-Akt signaling pathway, and Ras signaling pathway. However, in the TP53 wildtype cohorts, the primary pathways included the cancer pathway, PI3K-Akt signaling pathway, and Focal adhesion pathway.
Conclusions
There were characterized the genomic differences and similarities, stratified by the TP53 status, which may reflect the PC patients with TP53 mutation harbored specific molecular mechanism.Patients with TP53 wt are more likely to benefit from immunotherapy, PARPI.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
H. Wang: Financial interests, Personal, Full or part-time Employment: Beijing AcornMed Biotechnology Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
430P - Single-cell spatial architecture of tumour microenvironment in patients with in-transit melanoma (ITM)
Presenter: Camelia Quek
Session: Poster viewing 06
431P - Alveolar soft part sarcomas: A tertiary care Indian centre experience
Presenter: Jyoti Bajpai
Session: Poster viewing 06
432P - Representation of countries and gender in abstracts at the 2022 American Society of Clinical Oncology Annual Scientific Meeting (ASCO ASM)
Presenter: Laure-Anne Teuwen
Session: Poster viewing 06
433P - Variations in radiation oncology treatment access in Asia and its implications on cancer care
Presenter: Abhishek Krishna
Session: Poster viewing 06
434P - Outcome of high grade glioma patients: A single institution experience
Presenter: Adeeba Zaki
Session: Poster viewing 06
435P - The pattern of presentation of cancer in young adults from a tertiary care centre: A cause for concern
Presenter: Deepa Joseph
Session: Poster viewing 06
436P - Oncologic outcomes in patients with extraskeletal Ewing’s sarcoma (EES): A tertiary care centre experience
Presenter: Ashish Gulia
Session: Poster viewing 06
437P - The prevalence of burnout among medical oncology fellows-in-training in the Philippines: A cross-sectional study
Presenter: Daphne Lee
Session: Poster viewing 06
438P - Estimating scenarios for survival time in patients with metastatic melanoma receiving immunotherapy or targeted therapy
Presenter: Megan Smith-Uffen
Session: Poster viewing 06
439P - Evaluating Ewing’s sarcoma as the prototype for cancer care in teenage and young adults (TYA): A single-center retrospective cross-sectional study
Presenter: Pradeep Kumar Kistampally
Session: Poster viewing 06